Please join Insamo CEO Tim Craven in a conversation about "Undruggable Targets and the Advent of Generative AI" at?SynBioBeta?2024, happening on?May 7th?from 2:45 to 3:30 pm. We're diving deep into how generative AI is revolutionizing the hunt for new small molecule targets, especially those in previously inaccessible areas of biology. This session promises to be a fascinating exploration of the interface between advanced computing and biotechnology, showcasing how AI-driven approaches are opening doors to new therapeutic possibilities. We'll discuss the challenges, breakthroughs, and ethical considerations of using AI to navigate the complex landscape of 'undruggable' targets, highlighting the potential for significant medical advancements. #SynBioBeta2024
Insamo
生物技术研究
Pioneering the discovery of membrane-permeable and orally-available cyclic-peptides with antibody-like binding affinity.
关于我们
- 网站
-
www.insamo.com
Insamo的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 类型
- 私人持股
Insamo员工
动态
-
Insamo转发了
#Artificialintelligence is bridging the gap between #syntheticbiology and #medicine - Meet the innovative #companies leading the way: GRO Biosciences, Absci, Generate:Biomedicines, Insamo, Arvinas, Atomwise, Exscientia, Collaborative Drug Discovery - CDD Vault, CellVoyant, Asimov, Alltrna, BioLoomics, Inc., BigHat Biosciences, LabGenius, Profluent Bio, Arzeda, Dreamfold, VantAI, Hexagon Bio, bitBiome, Inc., Enveda Biosciences: https://lnkd.in/gTjz9aEd #SynBioBeta2024 #synbio #AI Thank you to Jenna Gallegos